Atara Biotherapeutics Operating Margin vs. Price To Book
| ATRA Stock | USD 6.50 -0.40 -5.80% |
Atara Biotherapeutics Operating Profit Margin | -0.61 |
The module aggregates profitability drivers for Atara Biotherapeutics with ratios tied to revenue, assets, and equity.
Trending Equities. Macro event markers
Earnings Share 2.86 | Revenue Per Share | Quarterly Revenue Growth -0.91 | Return On Assets | Return On Equity |
Investors evaluate Atara Biotherapeutics using market value and book value, each describing different facets of the business. Atara Biotherapeutics' market capitalization is 46.87 M. A P/B ratio of 1.97 indicates the market values Atara Biotherapeutics above its accounting book value. Enterprise value stands at 50.04 M. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
The concept of value for Atara Biotherapeutics differs from its quoted price, since each reflects a different lens. For Atara Biotherapeutics, key inputs include a P/B ratio of 1.97, a profit margin of 15.4%, ROE of -20.15%, and revenue of 128.94 M. Trading price represents the transaction level agreed by market participants.
Atara Biotherapeutics Price To Book vs. Operating Margin Fundamental Analysis
Peer comparison models estimate Atara Biotherapeutics's intrinsic positioning within its sector. Atara Biotherapeutics is rated fourth in operating margin among leading competitors. It is rated below average in price to book among leading competitors . Comparative financial data indicate that Operating Profit Margin is shifting by roughly 4.92%. Previously, Operating Profit Margin was valued at -0.58. Relative ratio analysis evaluates Atara Biotherapeutics's earnings valuation.Atara Price To Book vs. Operating Margin
Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Atara Biotherapeutics |
| = | -1.03 % |
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Atara Biotherapeutics |
| = | 1.97 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Atara Price To Book Comparison
Atara Biotherapeutics is currently under evaluation in price to book among leading competitors.
Atara Biotherapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Atara Biotherapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Atara Biotherapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Atara Biotherapeutics' change in net profit over the period of time. It can combine multiple indicators of Atara Biotherapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 9.2 K | 9.7 K | |
| Operating Income | -75.1 M | -78.8 M | |
| Income Before Tax | -76.9 M | -80.7 M | |
| Total Other Income Expense Net | -2.3 M | -2.2 M | |
| Net Loss | -76.9 M | -80.7 M | |
| Income Tax Expense | -10.8 K | -10.3 K | |
| Net Loss | -76.9 M | -80.7 M | |
| Non Operating Income Net Other | 60.1 M | 63.1 M | |
| Net Loss | -205.5 M | -215.7 M | |
| Interest Income | 2.4 M | 3.1 M | |
| Net Interest Income | -2.3 M | -2.1 M | |
| Change To Netincome | 4.1 M | 3.9 M | |
| Net Loss | -10.26 | -10.78 | |
| Income Quality | 0.72 | 0.56 | |
| Net Income Per E B T | 1.15 | 1.09 |
Atara Profitability Driver Comparison
Understanding Atara Biotherapeutics' profitability drivers is a critical part of evaluating Atara Biotherapeutics as an investment. Unexpected events - from regulatory changes to commodity price movements - can materially alter the profit trajectory and investment outlook during any given holding period.
Earnings per Share Projection vs Actual
Use Atara Biotherapeutics in pair-trading
Pair trading with Atara Biotherapeutics can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.
Atara Biotherapeutics Pair Trading
Atara Biotherapeutics Pair Trading Analysis
Identifying correlated replacements for Atara Biotherapeutics is particularly important in concentrated portfolios where Atara Biotherapeutics represents a large allocation. A poor substitute could introduce unintended factor or sector risks that persist beyond the required waiting period.
Correlation is not causation, but for Atara Biotherapeutics it is a practical tool. High correlations between Atara Biotherapeutics and a potential addition to the portfolio flag concentrated exposure, while low correlations signal diversification potential.
Correlation analysis and pair evaluation for Atara Biotherapeutics can support hedging context. The method can be applied across sectors and broader equity sets.Use Investing Themes to Complement your Atara Biotherapeutics position
Using Atara Biotherapeutics inside a theme workflow gives investors a structured way to compare related stocks, funds, ETFs, and crypto assets before allocating capital. The practical benefit is that the selected idea can be tuned either for higher upside or for tighter risk control.
Did You Try This Idea?
Run Large Blend Funds Thematic Idea Now
Large Blend Funds
Fund or Etfs that invest in stocks of large organizations that have characteristics of both growth and value companies. The Large Blend Funds theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large Blend Funds Theme or any other thematic opportunities.
| View All Next | Launch |
More Resources for Atara Stock Analysis
Reviewing Atara Biotherapeutics commonly begins with financial statements and performance trends. Financial ratios provide context for profitability, efficiency, and growth trends. Selected reports below provide context for Atara Stock:Trending Equities. Our How to Buy Atara Stock guide explains the steps to invest in Atara Biotherapeutics stock.Analysis related to Atara Biotherapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
A projection view for Atara Biotherapeutics starts with historical financial statements. The core view includes income statement, balance sheet, and cash flow.